AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead Sciences’ rival Trodelvy significantly improved OS in a prior late-phase study.
The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach of its clot-busting hardware.
Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after receiving encouraging phase 2 data in lung and eye cancers, respectively.
After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is expected to extend the biotech’s cash runway into the second half of 2026.
Context Therapeutics is building up its bank of bispecific antibody candidates. The Philadelphia-based company is paying $11 million upfront for a T-cell engaging antibody from BioAtla, according to a Sept. 23 SEC filing.
European stock markets end year with gains
U.S. stock markets will close on Thursday of next week in honor of former President Jimmy Carter, continuing a long-held Wall Street tradition in mourning the nation’s leaders
Data shows credit card defaults jumped 50% in 2024 from the year before to the highest since 2010
Stock indexes closed mostly lower on Wall Street on the final day of another record-setting year
Cataract removal is one of the oldest and most common surgeries in the world. A surgeon makes small incisions in the eye, sucks out the cloudy lens and replaces it with an artificial lens implant. Complications are rare but can range from blurred vision and light sensitivity to retinal detachment, which can lead to blindness if untreated.
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Jasper dials up dose after complete responses come and go quickly in hives trial
Novartis channels Gargamel, terminating midphase SMURF1 trial
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
